胰高血糖素样肽-1受体激动剂在多发性硬化中的应用：专题叙述性综述
Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review.
文献信息
| PMID | 42860897 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Audrey Y Chang |
| 作者单位 | Division of MS and Neuroimmunology, Davee Department of Neurology, Northwestern University, Chicago, Illinois, USA. |
| 期刊 | Annals of clinical and translational neurology |
| SCI 分区 | Q2 |
| IF | 4.4 |
| 研究类型 | 综述 Meta · 临床 |
| 所属专科 | 鼻科 |
中文摘要
胰高血糖素样肽-1（GLP-1）受体激动剂（RAs）是一类相对较新的药物，最初获美国食品药品监督管理局批准用于改善2型糖尿病患者的血糖控制，随后又用于肥胖患者的减重。多发性硬化（MS）常伴有GLP-1RAs适用指征的合并症。共病慢性病患病率的增加，使得因肥胖、糖尿病、阻塞性睡眠呼吸暂停、代谢相关脂肪性肝炎和/或慢性肾脏病等适应症而处方GLP-1RA的多发性硬化患者（pwMS）数量增多。本综述探讨以下关键问题：（1）GLP-1RAs用于pwMS和肥胖患者减重，包括与药物耐受性和安全性相关的考虑；（2）GLP-1RAs在pwMS中对其获批的非MS适应症的疗效；（3）GLP-1RAs在其获批适应症之外对MS疾病病程可能的多效性作用。
英文摘要
The glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity. Multiple sclerosis (MS) is commonly associated with comorbidities for which GLP-1RAs are indicated. An increasing prevalence of comorbid chronic diseases has increased the number of people living with MS (pwMS) who are prescribed a GLP-1RA, for indications of obesity, diabetes, obstructive sleep apnea, metabolic-associated steatohepatitis, and/or chronic kidney disease. This review addresses the following key considerations: (1) the use of GLP-1RAs for weight loss in pwMS and obesity, including considerations related to drug tolerability and safety; (2) the efficacy of the GLP-1RAs for their approved non-MS indications in pwMS; and (3) the potentially pleiotropic effects of the GLP-1RAs on the MS disease course beyond their approved indications.